Alterations of 3p21.31 tumor suppressor genes in head and neck squamous cell carcinoma: Correlation with progression and prognosis

International Journal of Cancer

Volumn 123, Issue 11, 2008, Pages 2594-2604

  Ghosh, Susmita ^a   Ghosh, Amlan ^a   Maiti, Guru Prasad ^a   Alam, Neyaz ^a   Roy, Anup ^b   Roy, Bidyut ^c   Roychoudhury, Susanta ^d   Panda, Chinmay Kumar ^a  

^a CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

^b MEDICAL COLLEGE AND HOSPITAL   (India)

^c INDIAN STATISTICAL INSTITUTE   (India)

^d INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

3p21.31; Dysplastic lesions; Expression; Head and neck squamous cell carcinoma; Methylation; Mutation; Survival study; Tumor suppressor genes

Indexed keywords

RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ADOLESCENT; ADULT; AGED; ARTICLE; CACNA2D2 GENE; CANCER CELL; CDC25A GENE; CHROMOSOME 3P; CONTROLLED STUDY; FEMALE; GENE; GENE DELETION; GENE MUTATION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIMD1 GENE; LTF GENE; MAJOR CLINICAL STUDY; MALE; METHYLATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCOTIN GENE; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

BASE SEQUENCE; CARCINOMA, SQUAMOUS CELL; CDC25 PHOSPHATASES; CHROMOSOMES, HUMAN, PAIR 3; DISEASE PROGRESSION; DNA METHYLATION; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEINS;

EID: 57349176947     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23834     Document Type: Article

References (58)

1. Tripathi A, Dasgupta S, Roy A, Sengupta A, Roy B, Roychudhury S, Panda CK. Sequential deletions in both arms of chromosome 9 are associated with the development of head and neck squamous cell carcinoma in Indian patients. J Exp Clin Cancer Res 2003;22:289-97.
2. Ha PK, Benoit NE, Yochem R, Sciubba J, Zahurak M, Sidransky D, Pevsner J, Westra WH, Califano J. A transcriptional progression model for head and neck cancer. Clin Cancer Res 2003;9:3058-64.
3. Uzawa N, Yoshida MA, Oshimaura M, Ikeuchi T. Suppression of tumorigenicity in three different cell lines of human oral squamous cell carcinoma by introduction of chromosome 3p via microcell mediated chromosome transfer. Oncogene 1995;11:1997-2004.
4. Perez-Ordonez BP, Beauchemin M, Jordan RC. Molecular biology of squamous cell carcinoma of the head and neck. J Clin Pathol 2006;59:445-53.
5. Dasgupta S, Mukherjee N, Roy S, Roy A, Sengupta A, Roychowdhury S, Panda CK. Mapping of candidate tumor suppressor genes' loci on human chromosome 3 in head and neck squamous cell carcinoma of Indian patient population. Oral Oncol 2002;38:6-15.
6. Chakraborty SB, Dasgupta S, Roy A, Sengupta A, Roy B, Roychowdhury S, Panda CK. Differential deletions in 3p are associated with the development of head and neck squamous cell carcinoma from Indian patients. Cancer Genet Cytogenet 2003;145:1-9.
7. Ji L, Minna JD, Roth JA. 3p21.3 Tumor suppressor cluster: prospects for translational applications. Future Oncol 2005;1:79-92.
8. Pan ZG, Kashuba VI, Liu XQ, Shao JY, Zhang RH, Jiang JH, Guo C, Zabarovsky E, Ernberg I, Zeng YX. High frequency somatic mutations in rassf1A in nasopharyngeal carcinoma. Cancer Biol Ther 2005;4:1116-22.
9. Qiu GH, Tan LK, Loh KS, Lim CY, Srivastava G, Tsai ST, Tsao SW, Tao Q. The candidate tumor suppressor gene BLU, located at the commonly deleted region 3p21.3, is an E2F-regulated, stress-responsive gene and inactivated by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma. Oncogene 2004;23:4793-806.
10. Hesson LB, Cooper WN, Latif F. Evaluation of the 3p21.3 tumor-suppressor gene cluster. Oncogene 2007;26;7283-301.
11. Frost GI, Mohapatra G, Wong TM, Csoka AB, Gray JW, Stern R. HYAL1LUCA-1, a candidate tumor suppressor gene on chromosome 3p21.3, is inactivated in head and neck squamous cell carcinomas by aberrant splicing of pre-mRNA. Oncogene 2000;19:870-8.
12. Gasparotto D, Maestro R, Piccinin S, Vukosavljevic T, Barzan L, Sulfaro S Boiocchi M. Overexpression of CDC25A and CDC25B in Head and Neck Cancers. Cancer Res 1997;57:2366-8.
13. Bourdon JC, Renzing J, Robertson PL, Fernandes KN, Lane DP. Scotin, a novel p53-inducible proapoptotic protein located in the ER and the nuclear membrane. J Cell Biol 2002;158:235-46.
14. Xiao Y, Monitto CL, Minhas KM, Sidransky D. Lactoferrin down-reguletes G1 Cyclin-dependent kinases during growth arrest of head and neck cancer cells. Clin Cancer Res 2004;10:8683-6.
15. Harmer MH, ed. UICC TNM classification of malignant tumors, 3rd edn. Geneva: Union Internationale Contre le Cancer (UICC), 1978.
16. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual, 2nd edn. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
17. Ichimura K, Bolin MB, Goike HM, Schmidt EE, Moshref A, Collins VP. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-s transition control gene abnormalities. Cancer Res 2000;60:417-24.
18. Loginov VI, Malyukova AV, Seryogin YA, Hodyrev DS, Kazubskaia TP, Ermilova VD, Garkavtseva RF, Kiselev LL, Zabarovsky ER, Braga EA. Methylation of the promoter region of the RASSF1A candidate tumor suppressor gene in primary epithelial tumors. Mol Biol 2004;38:654-67.
19. Ivanova T, Petrenko A, Gritsko T, Vinokourova S, Eshilev E, Kobzeva V, Kisseljov F, Kisseljova NP. Methylation and silencing of the retinoic acid receptor-β2 gene in cervical cancer. BMC Cancer. 2002;2:4.
20. Herman JG, Jeremy R, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands Proc Natl Acad Sci USA 1996;93:9821-6.
21. Burbee DG, Forgacs E, Zöchbauer-Müller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, Sekido Y, Latif F, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001;93:691-9.
22. Tripathi A, Banerjee S, Chunder N, Roy A, Roychowdhury S, Panda CK. Differential alterations of the genes in the CDKN2A-CCND1-CDK4-RB1 pathway are associated with the development of head and neck squamous cell carcinoma in Indian patients. J Can Res Clin Oncol 2003;129:642-50.
23. Dallol A, Da Silva NF, Viacava P, Minna JD, Bieche I, Maher ER, Latif F. SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast Cancers. Cancer Res 2002;62:5874-80.
24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) method. Methods 2001;25:402-8.
25. Perrone F, Suardi S, Dagrada G, Bossi P, Locati L, Pilotti S. Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. Clin Cancer Res 2006;12:6643-51.
26. Swan DC, Tucker RA, Tortolero-Luna G, Mitchell MF, Wideroff L, Unger ER, Nisenbaum RA, Reeves WC, Icenogle JP. Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type. J Clin Microbiol 1999;37:1030-4.
27. Mao L, Lee DJ, Tockman MS, Erozan YS, Askin F, Sidransky D. Microsatellite alterations as clonal markers for the detection of human cancer. Proc Natl Acad Sci USA 1994;91:9871-5.
28. Kholodnyuk ID, Kozireva S, Kost-Alimova M, Kashuba V, Klein G Imreh S. Down regulation of 3p genes. LTF, SLC38A3 and. DRR1, upon growth of human chromosome 3-mouse fibrosarcoma hybrids in severe combined immunodeficiency mice. Int J Cancer 2006;119:99-107.
29. Angeloni D. Molecular analysis of deletions in human chromosome 3p21 and the role of resident cancer genes in disease. Brief Funct Genom Proteom 2007;6:19-39.
30. Kost-Alimova M, Imreh S. Modeling non-random deletions in cancer. Semin Cancer Biol 2007;17:19-30.
31. Senchenko VN, Liu J, Loginov W, Bazov I, Angeloni D, Seryogin Y, Ermilova V, Kazubskaya T, Garkavtseva R, Zabarovska VI, Kashuba VI, Kisselev LL, et al. Discovery of frequent homozygous deletions in chromosome 3p21.3 LUCA and AP20 regions in renal, lung and breast carcinomas. Oncogene 2004;23:5719-28.
32. Imreh S, Klein G, Zabarovsky ER. Search for unknown tumor-antagonizing genes. Genes Chromosomes Cancer 2003;38:307-21.
33. Sharp TV, Munoz F, Darai E, Nicholson AG, Klein G, Imreh S, Boshoff C. LIM domains containing protein1 (LIMD1), a tumor suppressor encoded at chromosome 3p21.3, binds pRB and represses E2F-driven transcription. Proc Natl Acad Sci USA 2004;101:16531-6.
34. Iijima H, Tomizawa Y, Iwasaki Y, Sato K, Sunaga N, Dobashi K, Saito R, Nakajima T, Minna JD, Mori M. Genetic and epigenetic inactivation of LTF gene at 3p21.3 in lung cancers. Int J Cancer 2006;118:797-801.
35. Galaktionov K, Lee AK, Eckstein J, Draetta G, Meckler J, Loda M, Beach D. CDC25A phosphatases as potential human oncogenes. Science 1995;269:1575-7.
36. Wang Z, Wang M, Lazo JS, Carr BI. Identification of epidermal growth factor receptor as a target of Cdc25A protein phosphatase. J Biol Chem 2002;77:19470-5.
37. Dammann R, Schagdarsurengin U, Seidel C, Strunnikova M, Rastetter M, Baier K, Pfeifer GP. The tumor suppressor. RASSF1A in human carcinogenesis: an update. Histol Histopathol 2005;20:645-63.
38. Carboni GL, Gao B, Nishizaki M, Xu K, Minna JD, Roth JA, Ji L. CACNA2D2-mediated apoptosis in NSCLC cells is associated with alterations of the intracellular calcium signaling and disruption of mitochondria membrane integrity. Oncogene 2003;22:615-26.
39. Kulkarni V, Saranath D. Concurrent hypermethylation of multiple regulatory genes in chewing tobacco associated oral squamous cell carcinomas and adjacent normal tissues. Oral Oncol 2004;40:145-53.
40. Sengupta S, Chakrabarti S, Roy A, Panda CK, Roychoudhury S. Inactivation of hMLH1 and hMSH2 in HNSCC tumors and leukoplakia by promoter hypermethylation and its relation with MIN phenotype. Cancer 2007;109:703-12.
41. Huggins CJ, Gill M, Andrulis IL. Identification of rare variants in the hLIMD1 gene in breast cancer. Cancer Genet Cytogenet 2007;178:36-41.
42. Wegener S, Hampe W, Herrmann D, Schaller HC. Alternative splicing in the regulatory region of the human phosphatases CDC25A and CDC25C. Eur J Cell Biol 2000;79:810-15.
43. Dalal SN, Schweitzer CM, Gan J, DeCaprio JA. Cytoplasmic localization of human cdc25C during interphase requires an intact 14-3-3 binding site. Mol Cell Biol 1999;19:4465-79.
44. Yang J, Winkler K, Yoshida M, Kornbluth S. Maintenance of G2 arrest in the Xenopus oocyte: a role for 14-3-3-mediated inhibition of cdc25 nuclear import. EMBO J 1999;18:2174-83.
45. Agathanggelou A, Cooper WN, Latif F. Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res 2005;65:3497-508.
46. Feng Y, Zhao H, Luderer HF, Epple H, Ross FP, Teitelbaum SL, Longmore GD. The LIM protein, LIMD1, regulates AP-1 activation through an interaction with TRAF6 to influence osteoclast development. J Biol Chem 2006;282:39-48.
47. Tripathi A, Banerjee S, Chunder N, Roy A, Roychowdhury S, Panda CK. Differential alterations of the genes in the CDKN2A-CCND1-CDK4-RB1 pathway are associated with the development of head and neck squamous cell carcinoma in Indian patients. J Can Res Clin Oncol 2003;129:642-50.
48. Lerman MI, Minna JD. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. Cancer Res 2000;60:6116-33.
49. Chow LS, Lo KW, Kwong J, To KF, Tsang KS, Lam CW, Dammann R, Huang DP. RASSF1A is a target tumor suppressor from 3p21 in nasopharyngeal carcinoma. Int J Cancer 2004;109:839-47.
50. Karlsson-Rosenthal C, Millar JB. Cdc25: mechanisms of checkpoint inhibition and recovery. Trends in Cell Biol 2006;16:285-92.
51. Boutros R, Lobjois V, Ducommun B. CDC25 phosphatases in cancer cells: key players? Good target? Nat Rev Cancer 2007;7:495-507.
52. Kristjansdottir K, Rudolph J. Cdc25 phosphatases and cancer. Chem Biol 2004;11:1043-51.
53. Dong SM, Sun D-II, Benoit NE, Kuzmin I, Lerman MI, Sidransky D. Epigenetic inactivation of RASSF1A in head and neck cancer. Clin Cancer Res 2003;9(10, Part 1):3635-40.
54. Galaktionov K, Jessus C, Beach D. Raf1 interaction with cdc25 phosphatase ties mitogenic signal transduction to cell cycle activation. Genes Dev 1995;9:1046-58.
55. Xia K, Lee RS, Nasimhan RP, Mukhopadhyay NK, Neel BG, Roberts TM. Tyrosine phosphorylation of the proto-oncoprotein Raf-1 is regulated by Raf-1 itself and the phosphatase Cdc25A. Mol Cell Biol 1999;19:4819-24.
56. Nemoto K, Vogt A, Oguri T, Lazo LS. Activation of the Raf-1/MEK/Erk kinase pathway by a novel Cdc25A inhibitor in human prostate cancer cells. Prostate 2004;58:95-102.
57. Conklin DS, Galaktionov K, Beach D. 14-3-3 proteins associate with cdc25 phosphatases. Proc Natl Acad Sci USA 1995;92:7892-6.
58. Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J, Sasaki C, Joe J, Camp RL, Rimm DL, Psyrri A. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006 10;24:736-47.